Roth Capital Issues Pessimistic Forecast for MNMD Earnings

Key Points

• Roth Capital has lowered its Q3 2025 earnings per share (EPS) estimate for Mind Medicine (MindMed) to ($0.49), down from a previous estimate of ($0.39).
• The company's recent earnings report showed a loss of ($0.50) per share, missing analysts' expectations by ($0.12).
• Despite the earnings revision, Mind Medicine holds a consensus rating of "Buy" with an average price target of $24.71 from multiple analysts.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Investment analysts at Roth Capital cut their Q3 2025 earnings estimates for Mind Medicine (MindMed) in a research report issued on Monday, August 4th. Roth Capital analyst J. Wittes now expects that the company will earn ($0.49) per share for the quarter, down from their prior forecast of ($0.39). The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. Roth Capital also issued estimates for Mind Medicine (MindMed)'s Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($2.13) EPS, FY2027 earnings at $0.84 EPS, FY2028 earnings at $4.21 EPS and FY2029 earnings at $7.77 EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.12).

MNMD has been the subject of several other research reports. Chardan Capital reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Mind Medicine (MindMed) in a report on Friday, August 1st. Cantor Fitzgerald upgraded shares of Mind Medicine (MindMed) to a "strong-buy" rating in a research report on Tuesday, May 13th. Finally, Oppenheimer started coverage on Mind Medicine (MindMed) in a report on Monday. They issued an "outperform" rating and a $25.00 price target on the stock. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Mind Medicine (MindMed) presently has a consensus rating of "Buy" and an average target price of $24.71.

Mind Medicine (MindMed) Stock Performance

NASDAQ MNMD traded up $0.10 during trading hours on Wednesday, hitting $9.99. The company's stock had a trading volume of 959,982 shares, compared to its average volume of 1,290,042. Mind Medicine has a 12 month low of $4.70 and a 12 month high of $10.44. The company's 50 day simple moving average is $8.02 and its two-hundred day simple moving average is $7.19. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.98 and a quick ratio of 4.98. The company has a market cap of $754.77 million, a P/E ratio of -6.53 and a beta of 2.49.

Insider Activity at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 26,491 shares of the company's stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $6.80, for a total value of $180,138.80. Following the transaction, the chief executive officer directly owned 830,065 shares in the company, valued at $5,644,442. This represents a 3.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Sullivan sold 11,491 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $6.80, for a total transaction of $78,138.80. Following the sale, the insider directly owned 305,130 shares of the company's stock, valued at $2,074,884. This represents a 3.63% decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,830 shares of company stock worth $311,644 in the last 90 days. 2.45% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas boosted its stake in shares of Mind Medicine (MindMed) by 9.4% during the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company's stock valued at $106,000 after purchasing an additional 1,400 shares in the last quarter. CWM LLC lifted its holdings in Mind Medicine (MindMed) by 67.4% during the second quarter. CWM LLC now owns 4,459 shares of the company's stock worth $29,000 after buying an additional 1,796 shares during the period. Blair William & Co. IL boosted its position in Mind Medicine (MindMed) by 77.7% during the 2nd quarter. Blair William & Co. IL now owns 22,218 shares of the company's stock valued at $144,000 after acquiring an additional 9,718 shares in the last quarter. Palumbo Wealth Management LLC increased its holdings in shares of Mind Medicine (MindMed) by 6.3% in the 2nd quarter. Palumbo Wealth Management LLC now owns 24,043 shares of the company's stock valued at $156,000 after acquiring an additional 1,415 shares during the period. Finally, Bay Rivers Group bought a new position in shares of Mind Medicine (MindMed) in the 2nd quarter worth $75,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.